Skip to main content
main-content

01.06.2009 | Gastrointestinal Oncology | Ausgabe 6/2009

Annals of Surgical Oncology 6/2009

Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 6/2009
Autoren:
MD Béatrice Aussilhou, MD Safi Dokmak, MD Sandrine Faivre, MD Valérie Paradis, MD Valérie Vilgrain, MD Jacques Belghiti

Abstract

Background

This prospective study evaluated the effect of bevacizumab on the hypertrophy of the future liver remnant (FLR) after portal vein occlusion (PVO) before major hepatectomy for colorectal liver metastases.

Methods

Twenty-seven patients with colorectal liver metastases treated with preoperative FOLFOX/FOLFIRI chemotherapy regimen since 2002 were evaluated for the degree of hypertrophy of the FLR after right PVO. The results were compared with a similar group of 13 patients treated since 2006 with a chemotherapeutic regimen including bevacizumab and PVO. The FLR was measured by volumetric computed tomography 4 weeks before and after PVO.

Results

Before PVO, the FLR volumes were similar in the 13 patients who received bevacizumab (bev+) (mean ± standard deviation, 497 ± 136 cm3) and the 27 patients who did not receive bevacizumab (bev−) (511 ± 222 cm3, P = NS). After PVO, the increase in the FLR volume was significantly lower in the bev+ group (561 ± 171 cm3) compared with the bev− group (667 ± 213 cm3, P < .031). In the bev+ group, patients who had received six or more cycles and were ≥60 years old experienced far lower hypertrophy. A right hepatectomy was performed in 29 patients (72%) without mortality and no clinically important differences in morbidity.

Conclusions

Bevacizumab may impair hypertrophy of the FLR after PVO in preparation for major hepatectomy particularly, in patients aged ≥60 years and those who receive six or more cycles of bevacizumab, suggesting that major liver resection should be considered with caution in patients who have received bevacizumab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2009

Annals of Surgical Oncology 6/2009 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise